News

The company’s therapy, called 514G3, was developed from a human donor with natural antibodies effective at neutralizing MRSA and non-MRSA forms of S. aureus. According to the company,

CAT-1004 inhibits activated NF-kB, a protein that coordinates cellular response to muscular damage, stress and inflammation and plays a major role in muscle health. DMD involves progressive muscle

Acebilustat, a once-daily oral drug candidate, is currently being evaluated for the treatment of inflammatory diseases. The drug is a new small molecule inhibitor of Leukotriene A4 Hydrolase

The NDA is based on the results of a large, multicenter, open-label, randomized, Phase III trial that examined the repeated use of Amphora gel compared to a vaginal

Novella provides clinical trial services for small to mid-sized oncology companies. ImmunoCellular chief executive officer Andrew Gengos said: "Establishing this agreement with Novella Clinical moves us one more

Strensiq (asfotase alfa), a bone-targeted enzyme replacement therapy, is the first such treatment to be approved in Japan for HPP patients. The company intends to start commercial treatment

The deal amount was paid by Cardinal to Court Square Capital Partners using existing cash and new debt following the receipt of regulatory approvals and satisfying other customary

Horizon’s proposal represents a premium of 42 percent to the closing price of Depomed on July 6, 2015. The transaction, if consummated, would be immediately and substantially accretive

The agreement will offer an additional source of the dolutegravir active pharmaceutical ingredient (API), and will allow ViiV Healthcare to offer a competitive supply of the finished product